Kb 3 1

Manufactured by Merck Group

The KB-3-1 is a laboratory equipment product from Merck Group. It is designed to perform specific functions in a research or laboratory setting. The core functionality of the KB-3-1 is to facilitate controlled experimental processes, but a detailed description cannot be provided while maintaining an unbiased and factual approach.

Automatically generated - may contain errors

Lab products found in correlation

A2780, by Merck Group (2 mentions) Wi 38, by Merck Group (1 mentions) Hl 60, by Merck Group (1 mentions) Calcusyn software, by Biosoft (1 mentions) Sw480, by Merck Group (1 mentions) Wi 38, by American Type Culture Collection (1 mentions) Ccl 247, by American Type Culture Collection (1 mentions) Ccl 228, by American Type Culture Collection (1 mentions) Htb 79, by American Type Culture Collection (1 mentions) A2780cis, by Merck Group (1 mentions)

2 protocols using kb 3 1

Characterization of Drug-Resistant Cancer Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following human
cancer cell lines were used in this study: the colon carcinoma-derived
cell line SW480 and lung fibroblasts WI-38 (obtained from the American
Tissue Culture Collection), the ovarian carcinoma-derived cell line
A2780 (obtained from Sigma-Aldrich), the acute promyelocytic leukemia-derived
cell line HL-60 (obtained from Dr. M. Center, Kansas State University),
the cervix carcinoma-derived cell line KB-3-1 and the colchicine resistant
subline KBC-1 (obtained from Dr. D. W. Shen, Bethesda, Maryland).
SW480 and WI-38 cells were grown in MEM with 10% FCS and A2780, KB-3-1,
KBC-1, and HL-60 cells were cultured in RPMI 1640 supplemented with
10% FCS. SW480/Tria cells were generated by continuous exposure of
SW480 cells to increasing concentrations of Triapine (starting point,
0.05 μM; end point, 20 μM) over a period of one year.^{19 (link)} Triapine was administered to the cells once
every other week at the day after passage, when cells had attached
to the culture flasks.
Synergism is expressed by the combination
index (CI) according to Chou and Talalay^{49 (link)} using CalcuSyn software (Biosoft, Ferguson, MO, USA). CI < 0.9,
CI = 0.9–1.2, or CI > 1.2 represent synergism, additive
effects,
and antagonism, respectively.

Kowol C.R., Miklos W., Pfaff S., Hager S., Kallus S., Pelivan K., Kubanik M., Enyedy É.A., Berger W., Heffeter P, & Keppler B.K. (2016). Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. Journal of Medicinal Chemistry, 59(14), 6739-6752.

+ Open protocol

+ Expand

Culturing Diverse Cell Lines for Research

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell lines SW480 (Dukes’ type B, colorectal adenocarcinoma; ATCC^® CCL-228^™), HCT-116 (colorectal carcinoma; ATCC^® CCL-247^™), A2780 and A2780cis (ovarian carcinoma, Sigma), KB-3-1 (Human papillomavirus-related endocervical adenocarcinoma; HELA derivative, obtained from Dr. D. W. Shen, Bethesda, Maryland) VM47 (primary melanoma as described previously^{50 (link)}), H35 and H52 (primary glioblastoma as described previously^{51 (link)}) and Capan-1 (liver metastatic pancreatic cancer; ATCC^® HTB-79^™) were grown as a monolayer at 37 °C in a humified 5% CO₂ atmosphere. RPMI growth medium was supplemented with 10% fetal bovine serum (PAA, Linz, Austria). Cell cultures were periodically checked for Mycoplasma contamination. All media were supplemented with 2 mM MES buffer (pH 6, 1% vol) or H₂O (1% vol).

Alonso-de Castro S., Terenzi A., Hager S., Englinger B., Faraone A., Martínez J.C., Galanski M.S., Keppler B.K., Berger W, & Salassa L. (2018). Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. Scientific Reports, 8, 17198.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!